Table 1.
IC50 analyses of Adjudin and LND in a number of cancer cell lines Cells were plated at 5000/well in 96-well plates in replicates of 6, and treated with varying concentrations of Adjudin and LND the following day. After 24h treatment, the cell viability was assayed with a CCK8 kit. The absorbance at 450nm normalized to the level of control (indicative of the number of viable cells) were plotted against logarithmic value of the Adjudin and LND concentration (in log 10 µM) and the experiments were repeated three times at least. IC50 was determined from the graph in which the curve was obtained in SigmalPlot using 4-parameter logistic regression model; ND, not determined.
| Cell | Type | IC50 (µM)±SD |
|
|---|---|---|---|
| Adjudin | LND | ||
| A549 | Human lung adenocarcinoma cell |
63.1 ±1.7 | 205 ± 7.4 |
| H1299 | Human lung adenocarcinoma cell |
29 ± 2.4 | 266 ±4.2 |
| BGC-823 | Human gastric adenocarcinoma cell |
95.5 ±2.2 | ND |
| SGC-7901 | Human gastric adenocarcinoma cell |
58 ±1.4 | 117.2 ±4.8 |
| MKN45 | Human gastric adenocarcinoma cell |
64.6 ±1.6 | ND |
| MIA PaCa-2 | Human pancreatic adenocarcinoma cell |
52.7 ±2.2 | ND |
| MDA-MB-231 | Human breast adenocarcinoma cell |
13.8 ±3.4 | ND |
| U251 | Human glioma cell | 173.8 ±5.3 | ND |
| GL261 | Mouse glioma cell | 58.9 ±2.1 | 230.9 ±10 |
| Smmc-7721 | Human hepatoma cell | 72.3 3.4 | ND |
| HO-8910 | Human ovary adenocarcinoma cell |
55.8 ±1.8 | ND |
| PC-3 | Human prostate cancer cell | 93 ± 4.8 | 125.3 ±5 |
| Du145 | Human prostate cancer cell | 53.5 ±9.5 | >500 |
| L-929 | Mouse fibrosarcoma cell | 16.2 ±1 | ND |
| 4T1 | Mouse mammary tumor cell | 79.4 ± 2.4 | >300 |